Radioimmunotherapy - more promising than the long name

Radioimmunotherapy is the most promising treatment for lymphomas in many, many years. As I wrote earlier, monoclonal antibody breakthroughs allow a targeted approach to attacking cancer cells & leaving most healthy cells alone. Killing off the cancer cells often requires an extra punch. That's where the "radio-" part comes in. Using low dose isotopes of iodine or other elements attached to the antibody, it targets radiation right on top of the cancer cell and any other cancer cells in a very small area.



Gone are high radiation treatments of old which did not discriminate between the healthy & cancer cells. And the targeting is precise so your healthy cells don't have late effects (health problems later in life from treatment, not from the cancer).



If you have Non-Hodgkin's, talk to your doctor about the new immunotherapy treatments like Bexxar as their use is expanding.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap